Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice

Sung Ill Jang, Sungsoon Fang, Kwang Pyo Kim, Younhee Ko, Hyoseon Kim, Jieun Oh, Ga Young Hong, Su Yeon Lee, Joon Mee Kim, Ilkoo Noh, Dong Ki Lee

Research output: Contribution to journalArticle

Abstract

The increasing prevalence of cholesterol gallstone disease places an economic burden on the healthcare system. To identify novel therapeutics, we assessed the effects of n-3 polyunsaturated fatty acids (PUFA) in combination with UDCA in a mouse model of cholesterol gallstones. Gallstone dissolution, gallbladder wall thickness, mucin gene expression in the gallbladder, and levels of phospholipids, cholesterol, and bile acids in bile and serum were analysed. RNA was extracted from the liver for mRNA sequencing and gene expression profiling. Combination treatment resulted in greater gallstone dissolution compared with the control group, and PUFA and combination treatments reduced the thickness of the gallbladder wall. Expression levels of mucin genes were significantly lower in the UDCA, PUFA, and combination groups. Transcriptome analyses revealed that combination treatment modulated hepatic lipid metabolism. The PUFA and combination groups showed elevated bile phospholipid and bile acid levels and a lower cholesterol saturation index. Combination treatment with PUFA and UDCA dissolves cholesterol gallstones in mice by decreasing mucin production, increasing levels of phospholipids and bile acids in bile, and decreasing cholesterol saturation. Further studies of the therapeutic effects of combination PUFA and UDCA treatment in patients with cholesterol gallstones are warranted.

Original languageEnglish
Article number12740
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Ursodeoxycholic Acid
Omega-3 Fatty Acids
Gallstones
Cholesterol
Unsaturated Fatty Acids
Mucins
Gallbladder
Bile Acids and Salts
Bile
Phospholipids
Gene Expression Profiling
Therapeutic Uses
Therapeutics
Cost of Illness
Liver
Lipid Metabolism
RNA
Delivery of Health Care
Gene Expression
Control Groups

All Science Journal Classification (ASJC) codes

  • General

Cite this

Jang, Sung Ill ; Fang, Sungsoon ; Kim, Kwang Pyo ; Ko, Younhee ; Kim, Hyoseon ; Oh, Jieun ; Hong, Ga Young ; Lee, Su Yeon ; Kim, Joon Mee ; Noh, Ilkoo ; Lee, Dong Ki. / Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{f8288e3a9c2b49d19c7682fb927f2536,
title = "Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice",
abstract = "The increasing prevalence of cholesterol gallstone disease places an economic burden on the healthcare system. To identify novel therapeutics, we assessed the effects of n-3 polyunsaturated fatty acids (PUFA) in combination with UDCA in a mouse model of cholesterol gallstones. Gallstone dissolution, gallbladder wall thickness, mucin gene expression in the gallbladder, and levels of phospholipids, cholesterol, and bile acids in bile and serum were analysed. RNA was extracted from the liver for mRNA sequencing and gene expression profiling. Combination treatment resulted in greater gallstone dissolution compared with the control group, and PUFA and combination treatments reduced the thickness of the gallbladder wall. Expression levels of mucin genes were significantly lower in the UDCA, PUFA, and combination groups. Transcriptome analyses revealed that combination treatment modulated hepatic lipid metabolism. The PUFA and combination groups showed elevated bile phospholipid and bile acid levels and a lower cholesterol saturation index. Combination treatment with PUFA and UDCA dissolves cholesterol gallstones in mice by decreasing mucin production, increasing levels of phospholipids and bile acids in bile, and decreasing cholesterol saturation. Further studies of the therapeutic effects of combination PUFA and UDCA treatment in patients with cholesterol gallstones are warranted.",
author = "Jang, {Sung Ill} and Sungsoon Fang and Kim, {Kwang Pyo} and Younhee Ko and Hyoseon Kim and Jieun Oh and Hong, {Ga Young} and Lee, {Su Yeon} and Kim, {Joon Mee} and Ilkoo Noh and Lee, {Dong Ki}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-49095-z",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice. / Jang, Sung Ill; Fang, Sungsoon; Kim, Kwang Pyo; Ko, Younhee; Kim, Hyoseon; Oh, Jieun; Hong, Ga Young; Lee, Su Yeon; Kim, Joon Mee; Noh, Ilkoo; Lee, Dong Ki.

In: Scientific reports, Vol. 9, No. 1, 12740, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice

AU - Jang, Sung Ill

AU - Fang, Sungsoon

AU - Kim, Kwang Pyo

AU - Ko, Younhee

AU - Kim, Hyoseon

AU - Oh, Jieun

AU - Hong, Ga Young

AU - Lee, Su Yeon

AU - Kim, Joon Mee

AU - Noh, Ilkoo

AU - Lee, Dong Ki

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The increasing prevalence of cholesterol gallstone disease places an economic burden on the healthcare system. To identify novel therapeutics, we assessed the effects of n-3 polyunsaturated fatty acids (PUFA) in combination with UDCA in a mouse model of cholesterol gallstones. Gallstone dissolution, gallbladder wall thickness, mucin gene expression in the gallbladder, and levels of phospholipids, cholesterol, and bile acids in bile and serum were analysed. RNA was extracted from the liver for mRNA sequencing and gene expression profiling. Combination treatment resulted in greater gallstone dissolution compared with the control group, and PUFA and combination treatments reduced the thickness of the gallbladder wall. Expression levels of mucin genes were significantly lower in the UDCA, PUFA, and combination groups. Transcriptome analyses revealed that combination treatment modulated hepatic lipid metabolism. The PUFA and combination groups showed elevated bile phospholipid and bile acid levels and a lower cholesterol saturation index. Combination treatment with PUFA and UDCA dissolves cholesterol gallstones in mice by decreasing mucin production, increasing levels of phospholipids and bile acids in bile, and decreasing cholesterol saturation. Further studies of the therapeutic effects of combination PUFA and UDCA treatment in patients with cholesterol gallstones are warranted.

AB - The increasing prevalence of cholesterol gallstone disease places an economic burden on the healthcare system. To identify novel therapeutics, we assessed the effects of n-3 polyunsaturated fatty acids (PUFA) in combination with UDCA in a mouse model of cholesterol gallstones. Gallstone dissolution, gallbladder wall thickness, mucin gene expression in the gallbladder, and levels of phospholipids, cholesterol, and bile acids in bile and serum were analysed. RNA was extracted from the liver for mRNA sequencing and gene expression profiling. Combination treatment resulted in greater gallstone dissolution compared with the control group, and PUFA and combination treatments reduced the thickness of the gallbladder wall. Expression levels of mucin genes were significantly lower in the UDCA, PUFA, and combination groups. Transcriptome analyses revealed that combination treatment modulated hepatic lipid metabolism. The PUFA and combination groups showed elevated bile phospholipid and bile acid levels and a lower cholesterol saturation index. Combination treatment with PUFA and UDCA dissolves cholesterol gallstones in mice by decreasing mucin production, increasing levels of phospholipids and bile acids in bile, and decreasing cholesterol saturation. Further studies of the therapeutic effects of combination PUFA and UDCA treatment in patients with cholesterol gallstones are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85071739847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071739847&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-49095-z

DO - 10.1038/s41598-019-49095-z

M3 - Article

C2 - 31484954

AN - SCOPUS:85071739847

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 12740

ER -